Mirum Pharmaceuticals Reports Unprecedented Success in Hepatitis D Treatment Trial
Amsterdam, Monday 27 April 2026
Today, Mirum Pharmaceuticals revealed its Hepatitis D treatment achieved an extraordinary 100 per cent patient response rate, setting a new clinical benchmark likely to influence European biotech valuations.
Setting a New Clinical Benchmark
On 27 April 2026, California-based Mirum Pharmaceuticals published an 8-K filing detailing the Phase 2b portion of its AZURE-1 clinical trial [2]. The study evaluated brelovitug, an investigational antibody, in 53 patients suffering from chronic hepatitis delta virus (HDV) over a 24-week period [2]. The results were unequivocal: patients in the 300 mg once-weekly treatment arm achieved a 100 per cent virologic response, defined as a minimum 2 log10 reduction in HDV RNA from baseline or undetectable levels [2]. In contrast, the 900 mg dose administered every four weeks yielded a 75 per cent response rate, while the delayed treatment control group saw a 0 per cent response [2].
Implications for European Biotech and Spin-offs
For the broader Life Sciences and Health (LSH) ecosystem, particularly venture-backed university spin-offs in the Benelux region, Mirum’s data establishes a formidable new efficacy threshold [GPT]. The trial demonstrated that the 300 mg weekly dose was 33.333 per cent more effective in achieving a virologic response than the 900 mg monthly dose [2]. Such absolute clinical clarity forces European biotech firms developing competing virology or hepatology treatments to re-evaluate their own lab-to-market pipelines [GPT]. Start-ups seeking Series B or C funding will now likely be benchmarked against this 100 per cent virologic clearance rate, potentially impacting their competitive valuations during future capital raises [GPT].
Accelerating the Lab-to-Market Transition
Looking ahead, the clinical and regulatory timeline for brelovitug is advancing rapidly. Topline data from the broader Phase 3 AZURE-1 and AZURE-4 studies are anticipated in the second half of 2026 [2]. Should these late-stage trials replicate the Phase 2b success, Mirum expects to submit a Biologics License Application (BLA) and target a commercial launch in the United States by 2027 [2].